NCT03200834Active, not recruiting
Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)
Source: ClinicalTrials.gov · Last updated 26 Mar 2025
Brief summary (registry, in English)
Comparing different method of surgical technique D2 lymph node dissection vs D3 for right colon cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 239 (actual)
- First submitted
- 25 Mar 2017
- Start date
- 25 Jan 2017
- Primary completion date
- 3 Jan 2029
- Lead sponsor
- G.V. Bondar Republican Cancer Center
- Diseases
- Colorectal cancer
- NCT number
- NCT03200834
What you commit to
- Study type: Interventional
- Participants enrolled: 239
- From 25 Jan 2017 to the primary completion date, 3 Jan 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radiotherapy or chemotherapy
Other illness
- Complications of tumor (perforation and full bowel obstruction)
Other
- Patients with distant metastases
- Tumors T1-2 (I stage)
- Synchronous or metachronous tumors
- Women during Pregnancy or breast feeding period
Who the study is looking for
- Agreement of the patient to participate in trial
- Colon cancer (only adenocarcinoma )
- The tumor located between the cecum and the right 1/3 of transverse colon
- Tumors T3,Т4а,b N0-2 (II-III stages)
- Tolerance of chemotherapy
- ECOG 0-2
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| G.V. Bondar Republican Cancer Center Coordinator of this site? Confirm its status | Donetsk | Ukraine | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.